Lucid Diagnostics offers the EsoGuard DNA test, a non-invasive diagnostic tool that utilizes next-generation sequencing to detect biomarkers for esophageal precancer during a simple office visit. This technology enables early identification of Barrett's esophagus, significantly improving patient outcomes and reducing the risk of progression to esophageal cancer.
Funding
$21.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Esophageal cancer often develops from Barrett's esophagus, a precancerous condition that frequently goes undetected due to a lack of widespread, accessible screening methods. Traditional diagnostic methods like endoscopy are invasive, costly, and may deter at-risk individuals from undergoing regular screening. This results in delayed diagnoses and poorer outcomes for patients with esophageal cancer.
Solution
Lucid Diagnostics offers the EsoGuard DNA test, a non-invasive diagnostic tool designed for early detection of esophageal precancer. The test utilizes next-generation sequencing to analyze DNA biomarkers collected during a simple, in-office esophageal swab. This approach enables clinicians to identify Barrett's esophagus in at-risk patients without the need for endoscopy. Early detection through EsoGuard allows for timely intervention and management of the condition, potentially preventing progression to esophageal cancer and improving patient survival rates.
Target Audience
The primary target audience includes gastroenterologists, primary care physicians, and other healthcare providers who manage patients at risk for Barrett's esophagus and esophageal cancer, such as those with chronic acid reflux or a family history of the disease.
Features
- Non-invasive sample collection via esophageal swab, performed in a standard office setting
- Targeted next-generation sequencing to identify DNA biomarkers associated with Barrett's esophagus
- High sensitivity and specificity for detecting esophageal precancerous changes
- Results available to clinicians to guide patient management decisions